Wyeth Peer Comparison

NSE: WYETH | BSE: 500095

₹1,333.85

₹-30.50 (-2.24%)

As on 09-Dec-2014IST

Market cap

₹3,032 Cr

Revenue (TTM)

₹742 Cr

P/E Ratio

27.7

P/B Ratio

9.2

Div. Yield

10.9 %

Edit

	Wyeth	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Market cap (₹ Cr)	3,032	32,053	31,134	30,363	28,411
Revenue (₹ Cr)	742	1,593	9,779	3,751	1,936
Net Profit (₹ Cr)	109.38	438.64	-270.51	405.00	288.22
Net Margin (%)	14.24	27.16	-2.71	10.48	14.79
RoE (%)	36.42	25.02	-2.55	7.91	29.77
Price to Earnings	27.72	72.99	--	74.06	98.58
Price-To-Book	9.15	17.26	3.82	5.89	21.17

Income Statement (₹ Cr)

	Wyeth	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Operating Revenue	679.33	76.11	--	4,830.36	41.58
Total Income	714.07	76.68	--	4,914.64	41.73
Total Expenditure	577.01	69.99	--	3,850.53	30.00
EBITDA	102.32	6.12	--	979.83	11.59
Depreciation	2.74	0.80	--	139.92	3.35
EBIT	99.58	5.32	--	839.91	8.24
Interest	0.44	1.58	--	83.35	2.34
Other Income	34.74	0.56	--	84.28	0.14
Exceptional Items	--	--	--	49.83	--
Profit before Tax	133.88	4.31	--	890.67	6.04
Provision for Tax	45.96	1.44	--	47.88	1.54
Profit after Tax	87.92	2.86	--	842.79	4.50

	Wyeth	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Shareholder's Funds	269.29	10.77	--	3,581.47	44.83
Minority Interest	--	--	--	136.17	--
Non-Current Liabilities	6.78	1.29	--	1,161.18	10.36
Current Liabilities	208.12	26.33	--	1,743.20	21.34
Total Liabilities	503.72	38.71	--	6,622.02	76.53

	Wyeth	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Non-Current Assets	87.79	7.38	--	3,266.10	51.75
Current Assets	396.40	31.01	--	3,355.92	24.78
Total Assets	503.72	38.71	--	6,622.02	76.53
Total Debt*	2.50	12.17	--	1,906.08	21.09
Net Current Assets	188.28	4.68	--	1,612.72	3.44
Contingent Liabilities	126.37	--	--	267.40	4.70

	Wyeth	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Cash From Operating Activities	118.83	-0.21	--	1,476.29	6.29
Cash Flow from Investing Activities	28.69	-2.00	--	-851.62	-5.46
Cash from Financing Activities	-429.59	2.17	--	-601.32	-0.58
Net Cash Inflow / Outflow	-282.08	-0.04	--	23.35	0.25

	Wyeth	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
ROCE (%)	31.94	29.97	--	18.98	13.38
ROE (%)	21.03	30.26	--	30.04	19.08
ROA (%)	13.92	8.85	--	13.36	6.16
EBIT Margin (%)	20.18	8.78	--	22.03	28.21
Net Margin (%)	12.31	3.74	--	17.15	10.78
Cash Profit Margin (%)	12.93	4.81	--	20.32	18.86

	Wyeth	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Revenue Growth (%)	0.15	37.10	--	-13.89	12.11
EBIT Growth (%)	-30.42	30.95	--	-49.66	21.82
Net Profit Growth (%)	-32.40	39.55	--	-46.64	58.36
EPS Growth (%)	-32.40	39.55	--	-56.04	58.36
Book Value Growth (%)	-52.49	32.03	--	36.37	21.09

	Wyeth	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Price / Earnings	23.01	0.00	--	6.59	0.00
Price / Book Value	7.51	0.00	--	1.55	0.00
Dividend Yield (%)	16.29	--	--	2.19	--
EV/EBITDA	13.63	2.02	--	5.73	3.52
Market Cap (₹ Cr)	2,022.77	0.00	--	5,016.58	0.00

	Wyeth	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Debt to Equity	0.01	1.13	--	0.54	0.47
Short term debt to equity ratio	--	0.84	--	0.06	0.23
Current Ratio	1.90	1.18	--	1.93	1.16
Quick Ratio	1.14	0.75	--	1.36	1.11
Interest Coverage	305.90	3.73	--	11.69	3.58

	Wyeth	Acutaas Chemicals	Piramal Pharma	Wockhardt	Rubicon Research
Debtors to sales (%)	7.36	17.81	--	9.96	33.85
Asset Turnover	1.11	2.35	--	0.77	0.57
Receivable days	24.61	58.46	--	54.33	106.93
Inventory Days	89.51	41.85	--	77.43	10.49
Payable days	158.44	91.25	--	120.43	213.33
Cash Conversion Cycle	-44.33	9.06	--	11.32	-95.91

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.